reports
Hybridan Small Cap Feast - 12 Feb 24
12th February 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obj...
Scheme Effective
Arix Bioscience PLC (ARIX) Scheme Effective 12-Feb-2024 / 12:00 GMT/BST THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM, THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. FOR IMMEDIATE RELEASE Legal En...
Suspension of Trading in Shares
Arix Bioscience PLC (ARIX) Suspension of Trading in Shares 12-Feb-2024 / 07:00 GMT/BST THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM, THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. FOR IMMEDIATE RE...
Transaction Update
Arix Bioscience PLC (ARIX) Transaction Update 07-Feb-2024 / 11:30 GMT/BST THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM, THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. FOR IMMEDIATE RELEASE Legal ...
Results of First General Meeting
Arix Bioscience PLC (ARIX) Results of First General Meeting 29-Jan-2024 / 12:15 GMT/BST THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM, THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. FOR IMMEDIATE R...
Holding(s) in Company
Arix Bioscience PLC (ARIX) Holding(s) in Company 24-Jan-2024 / 17:30 GMT/BST TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Arix Bioscience Plc 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) Non-UK issuer 2. Reason fo...
Holding(s) in Company
Arix Bioscience PLC (ARIX) Holding(s) in Company 24-Jan-2024 / 17:30 GMT/BST TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BDO45071 Issuer Name Arix Bioscience plc UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Acacia Research Corporation City of registered office (if applicable) Country of registered office (if applicable) 4. Details of the shareholder Name...
Update on the Scheme and Publication of Notice of Second General Meeti...
Arix Bioscience PLC (ARIX) Update on the Scheme and Publication of Notice of Second General Meeting 23-Jan-2024 / 07:00 GMT/BST THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM, THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATION...
Unaudited NAV for December 2023
Arix Bioscience PLC (ARIX) Unaudited NAV for December 2023 19-Jan-2024 / 07:00 GMT/BST Arix Bioscience plc Unaudited NAV for December 2023 LONDON, 19 January 2024: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited estimated Net Asset Value (“NAV”) of the Company for the date ended 31 December 2023 as follows: Date NAV Breakdown Total NAV NAV per share Listed Portfolio Unliste...
Financial update on Harpoon Therapeutics acquisition by Merck (MSD)
Arix Bioscience PLC (ARIX) Financial update on Harpoon Therapeutics acquisition by Merck (MSD) 19-Jan-2024 / 07:01 GMT/BST Arix Bioscience plc Financial update on Harpoon Therapeutics acquisition by Merck (MSD) LONDON, 19 January 2024: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, provides a financial update on its expected returns from the Harpoon Therapeutics (NASDAQ: HARP) ("Harpoon") acquisition by Merck (NYSE: MRK) following the announcement that Merck (known as MSD ...
Portfolio company Harpoon Therapeutics to be acquired by Merck (MSD)
Arix Bioscience PLC (ARIX) Portfolio company Harpoon Therapeutics to be acquired by Merck (MSD) 08-Jan-2024 / 17:15 GMT/BST Arix Bioscience plc Portfolio company Harpoon Therapeutics to be acquired by Merck (MSD) LONDON, 8 January 2024: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, is pleased to note that its portfolio company, Harpoon Therapeutics (NASDAQ: HARP), is to be acquired by Merck (NYSE: MRK). The two companies have entered into a definitive agr...
Publication of Circular and RTW Bio Prospectus
Arix Bioscience PLC (ARIX) Publication of Circular and RTW Bio Prospectus 05-Jan-2024 / 07:00 GMT/BST THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM, THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. T...
Holding(s) in Company
Arix Bioscience PLC (ARIX) Holding(s) in Company 04-Jan-2024 / 17:30 GMT/BST TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: ARIX Bioscience PLC 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) Non-UK issuer 2. Reaso...
Update regarding timing of Proposed Scheme of Reconstruction
Arix Bioscience PLC (ARIX) Update regarding timing of Proposed Scheme of Reconstruction 22-Dec-2023 / 11:00 GMT/BST THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM, THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JU...
Unaudited NAV for November 2023
Arix Bioscience PLC (ARIX) Unaudited NAV for November 2023 13-Dec-2023 / 07:00 GMT/BST Arix Bioscience plc Unaudited NAV for November 2023 LONDON, 13 December 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited estimated Net Asset Value (“NAV”) of the Company for the date ended 30 November 2023 as follows: Date NAV Breakdown Total NAV NAV per share Listed Portfolio Un...
Portfolio Company Aura Biosciences Announces First Patient Dosed in Gl...
Arix Bioscience PLC (ARIX) Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial 08-Dec-2023 / 07:00 GMT/BST Arix Bioscience plc Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma LONDON, 8 December 2023: Arix Bioscience plc (“Arix”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, notes that its...
Correction: Portfolio Company Aura Biosciences Announces Closing of $9...
Arix Bioscience PLC (ARIX) Correction: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock 13-Nov-2023 / 16:00 GMT/BST The following amendment has been made to the “Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock” announcement released on 10/11/2023 at 08:00 GMT under EQS News ID 1770215. Some definitions of the “Company” have been amended to reflect the defined name of the portfolio company, “Aura”, throughout the release. All other information remains unchanged. The fully ...
Arix Bioscience: 1 director
A director at Arix Bioscience bought 25,000 shares at 113p and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Portfolio Company Aura Biosciences Announces Closing of $99 million Pu...
Arix Bioscience PLC (ARIX) Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock 10-Nov-2023 / 08:00 GMT/BST Arix Bioscience plc Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock LONDON, 10 November 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, notes that its Core Portfolio company, Aura Biosciences (NASDAQ: AURA) (“Aura”), has announced the closing of its und...
PDMR Notification & Director Shareholding
Arix Bioscience PLC (ARIX) PDMR Notification & Director Shareholding 10-Nov-2023 / 07:00 GMT/BST Arix Bioscience plc("Company") PDMR Notification & Director Shareholding Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them The Company has been notified that Andrew Smith, Non-Executive Director of the Company purchased 25,000 Ordinary shares of 0.001 pence each in the Company (“Shares”) on 9th November 2023 at a price of £1.13 per share. 1 Details of the person disch...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.